DelveInsight’s, “Bile Duct Cancer (Cholangiocarcinoma) Pipeline Insight” report provides comprehensive insights about 50+ companies and 60+ pipeline drugs in Bile Duct Cancer (Cholangiocarcinoma) pipeline landscape. It covers the Bile Duct Cancer (Cholangiocarcinoma) pipeline drug profiles, including clinical and nonclinical stage products. It also covers the Bile Duct Cancer (Cholangiocarcinoma) therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.
Stay ahead with the latest insights! Download DelveInsight’s comprehensive Bile Duct Cancer (Cholangiocarcinoma) Pipeline Report to explore emerging therapies, key Bile Duct Cancer (Cholangiocarcinoma) Companies, and future Bile Duct Cancer (Cholangiocarcinoma) treatment landscapes @ Bile Duct Cancer (Cholangiocarcinoma) Pipeline Outlook Report
Key Takeaways from the Bile Duct Cancer (Cholangiocarcinoma) Pipeline Report
- In February 2025:- Servier Affaires Medicales:- A Phase 3b research study to consolidate the data that ivosidenib is safe and effective in adult patients with previously treated, locally advanced, or metastatic cholangiocarcinoma (CCA). All patients who meet inclusion criteria will be enrolled to receive ivosidenib tablets orally once daily for 28 day cycles, continuing as long as clinical benefit and consent for participation is maintained.
- In February 2025:- Eisai Co. Ltd:- The primary purpose of the study is to assess the objective response rate (ORR) of E7090 by Response Evaluation Criteria In Solid Tumors (RECIST) 1.1 based on independent imaging review (IIR) in participants with unresectable cholangiocarcinoma with FGFR2 gene fusion who failed gemcitabine-based combination chemotherapy.
- In February 2025:- Taiho Oncology Inc.:- This is an open-label, multinational, randomized Phase 2 study confirming the clinical benefit of 20 mg futibatinib and evaluating the safety and efficacy of 16 mg futibatinib in previously treated CCA harboring FGFR2 gene fusions and other rearrangements.
- In February 2025:- Medivir:- This is an open-label, multicentre dose escalation/expansion study to assess safety and tolerability of MIV 818 as either monotherapy or in combination with 1) lenvatinib, a tyrosine kinase inhibitor used as a standard of care for the treatment of HCC or 2) pembrolizumab, a PD-1 inhibitor. The monotherapy parts of the study will include patients with various solid tumours that have spread to the liver, or alternatively originating in the liver. Evaluations of MIV-818 in combination with lenvatinib or pembrolizumab will only include patients with HCC.
- In February 2025:- Bold Therapeutics Inc.:- BOLD-100 is an intravenously administered sterile solution containing the ruthenium-based small molecule. BOLD-100 has been shown to preferentially decrease the expression of GRP78 in tumour cells and ER stressed cells when compared to normal cells. BOLD-100 will be combined with cytotoxic FOLFOX chemotherapy in this study, with a dose escalation cohort to ensure tolerability and safety, followed by a cohort expansion phase.
- In February 2025:- Seagen Inc.:- This trial studies tucatinib to find out if it is safe when given with trastuzumab and other anti-cancer drugs (pembrolizumab, FOLFOX, and CAPOX). It will look at what side effects happen when participants take this combination of drugs. A side effect is anything the drug does other than treating cancer. It will also look at whether tucatinib works with these drugs to treat certain types of cancer.
- In February 2025:- Apollo Therapeutics Ltd.:- This is an open-label, Phase 1/2 study to determine the safety, tolerability, and efficacy of APL-5125 for the treatment of selected locally advanced or metastatic solid tumors with particular focus on Colorectal carcinoma (CRC).
- In February 2025:- Janssen Research & Development LLC:- The primary purpose of this study is to evaluate objective response rate (ORR) as per Response Evaluation Criteria in Solid Tumors (RECIST) 1.1 of erdafitinib in a molecularly-defined subset of Asian participants with non-small-cell lung cancer (NSCLC), urothelial cancer, esophageal cancer and cholangiocarcinoma.
- In February 2025:- PureTech:- A Phase 1/2 Open-label, Multi-center Study of the Safety, Pharmacokinetics, and Anti-tumor Activity of LYT-200 Alone and in Combination with Chemotherapy or Tislelizumab in Patients with Metastatic Solid Tumors. This is an open-label, uncontrolled, multicenter Phase 1/2 study with a dose escalation phase (Part 1) and a cohort expansion phase (Part 2) in patients with relapsed/refractory metastatic solid tumors.
- DelveInsight’s Bile Duct Cancer (Cholangiocarcinoma) pipeline report depicts a robust space with 50+ active players working to develop 60+ pipeline therapies for Bile Duct Cancer (Cholangiocarcinoma) treatment.
- The leading Bile Duct Cancer (Cholangiocarcinoma) Companies such as Wellmarker Bio, Virogin Biotech Canada, TransThera Sciences, Tango Therapeutics, Taiho Oncology, Tyra Biosciences, Anheart Therapeutics, Nuvalent, Array BioPharma, InnoCare Pharma, NextPoint Therapeutics, and others.
- Promising Bile Duct Cancer (Cholangiocarcinoma) Therapies such as GNS561 + Trametinib, Tinengotinib 8 mg, Durvalumab, E7090, Pemigatinib, Gemcitabine, Cisplatin, Ivosidenib, and others.
Discover how the Bile Duct Cancer (Cholangiocarcinoma) treatment paradigm is evolving. Access DelveInsight’s in-depth Bile Duct Cancer (Cholangiocarcinoma) Pipeline Analysis for a closer look at promising breakthroughs @ Bile Duct Cancer (Cholangiocarcinoma) Clinical Trials and Studies
Bile Duct Cancer (Cholangiocarcinoma) Emerging Drugs Profile
- TT-00420: TransThera Biosciences
TT-00420 is an innovative, global phase III stage spectrum-selective kinase inhibitor that exerts antitumor effects by targeting tumor cells and improving the tumor microenvironment. Ongoing clinical trials in the US and China have revealed the potential of TT-00420 to be efficacious in various solid tumors. It was granted the Orphan-Drug Designation and Fast Track Designation by the FDA for the treatment of CCA. In July 2023, TT-00420 was granted the Breakthrough Therapy Designation (BTD) by NMPA in China.
- VG161: Virogin Biotech
VG161, Virogin’s pioneering oncolytic virus built on the company’s proprietary SynerlyticTM Platform, is an attenuated herpes simplex virus type 1 (HSV-1) armed with multiple payloads of IL12 & IL15/IL15Ra and a unique PD-L1 blocking peptide. The neurovirulence of wild-type HSV-1 is mitigated by the deletion of ICP 34.5 gene. These payloads can synergistically stimulate both innate and adaptive anti-tumor immunity in the tumor microenvironment. VG161 has been confirmed to be safe and effective in many tumor xenograft mouse models and in GLP toxicity studies preclinically. Currently, the drug is in Phase II stage of its clinical trial for the treatment of Cholangiocarcinoma.
- NXP800: Nuvectis Pharma
NXP800 is an oral, small molecule, potentially first-in-class GCN2 kinase activator. NXP800 is also being evaluated in an investigator-initiated study conducted in collaboration with the Mayo Clinic for the treatment of cholangiocarcinoma, an indication for which the FDA granted NXP800 Orphan Drug Designation. The NXP800 development program in platinum-resistant, ARID1a-mutated ovarian cancer was granted Fast Track Designation by the FDA. NXP800 completed a Phase 1a dose-escalation study in the first half of 2023. Currently, the drug is in Phase I stage of its clinical trial for the treatment of Cholangiocarcinoma.
The Bile Duct Cancer (Cholangiocarcinoma) pipeline report provides insights into
- The report provides detailed insights about companies that are developing therapies for the treatment of Bile Duct Cancer (Cholangiocarcinoma) with aggregate therapies developed by each company for the same.
- It accesses the Different therapeutic candidates segmented into early-stage, mid-stage, and late-stage of development for Bile Duct Cancer (Cholangiocarcinoma) Treatment.
- Bile Duct Cancer (Cholangiocarcinoma) Companies are involved in targeted therapeutics development with respective active and inactive (dormant or discontinued) projects.
- Bile Duct Cancer (Cholangiocarcinoma) Drugs under development based on the stage of development, route of administration, target receptor, monotherapy or combination therapy, a different mechanism of action, and molecular type.
- Detailed analysis of collaborations (company-company collaborations and company-academia collaborations), licensing agreement and financing details for future advancement of the Bile Duct Cancer (Cholangiocarcinoma) market.
Get a detailed analysis of the latest innovations in the Bile Duct Cancer (Cholangiocarcinoma) pipeline. Explore DelveInsight’s expert-driven report today! @ Bile Duct Cancer (Cholangiocarcinoma) Unmet Needs
Bile Duct Cancer (Cholangiocarcinoma) Companies
Wellmarker Bio, Virogin Biotech Canada, TransThera Sciences, Tango Therapeutics, Taiho Oncology, Tyra Biosciences, Anheart Therapeutics, Nuvalent, Array BioPharma, InnoCare Pharma, NextPoint Therapeutics, and others.
Bile Duct Cancer (Cholangiocarcinoma) pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration
- Oral
- Intravenous
- Subcutaneous
- Parenteral
- Topical
Bile Duct Cancer (Cholangiocarcinoma) Products have been categorized under various Molecule types such as
- Recombinant fusion proteins
- Small molecule
- Monoclonal antibody
- Peptide
- Polymer
- Gene therapy
Download DelveInsight’s latest report to gain strategic insights into upcoming Bile Duct Cancer (Cholangiocarcinoma) Therapies and key Bile Duct Cancer (Cholangiocarcinoma) Developments @ Bile Duct Cancer (Cholangiocarcinoma) Market Drivers and Barriers, and Future Perspectives
Scope of the Bile Duct Cancer (Cholangiocarcinoma) Pipeline Report
- Coverage- Global
- Bile Duct Cancer (Cholangiocarcinoma) Companies- Wellmarker Bio, Virogin Biotech Canada, TransThera Sciences, Tango Therapeutics, Taiho Oncology, Tyra Biosciences, Anheart Therapeutics, Nuvalent, Array BioPharma, InnoCare Pharma, NextPoint Therapeutics, and others.
- Bile Duct Cancer (Cholangiocarcinoma) Therapies- GNS561 + Trametinib, Tinengotinib 8 mg, Durvalumab, E7090, Pemigatinib, Gemcitabine, Cisplatin, Ivosidenib, and others.
- Bile Duct Cancer (Cholangiocarcinoma) Therapeutic Assessment by Product Type: Mono, Combination, Mono/Combination
- Bile Duct Cancer (Cholangiocarcinoma) Therapeutic Assessment by Clinical Stages: Discovery, Pre-clinical, Phase I, Phase II, Phase III
Which companies are leading the race in Bile Duct Cancer (Cholangiocarcinoma) drug development? Find out in DelveInsight’s exclusive Bile Duct Cancer (Cholangiocarcinoma) Pipeline Report—access it now! @ Bile Duct Cancer (Cholangiocarcinoma) Emerging Drugs and Major Companies
Table of Content
- Introduction
- Executive Summary
- Bile Duct Cancer (Cholangiocarcinoma): Overview
- Pipeline Therapeutics
- Therapeutic Assessment
- Bile Duct Cancer (Cholangiocarcinoma)– DelveInsight’s Analytical Perspective
- Late Stage Products (Phase III)
- TT-00420: TransThera Biosciences
- Drug profiles in the detailed report…..
- Mid Stage Products (Phase II)
- VG161: Virogin Biotech
- Drug profiles in the detailed report…..
- Early Stage Products (Phase I)
- NXP800: Nuvectis Pharma
- Drug profiles in the detailed report…..
- Preclinical and Discovery Stage Products
- Drug name: Company name
- Drug profiles in the detailed report…..
- Inactive Products
- Bile Duct Cancer (Cholangiocarcinoma) Key Companies
- Bile Duct Cancer (Cholangiocarcinoma) Key Products
- Bile Duct Cancer (Cholangiocarcinoma)- Unmet Needs
- Bile Duct Cancer (Cholangiocarcinoma)- Market Drivers and Barriers
- Bile Duct Cancer (Cholangiocarcinoma)- Future Perspectives and Conclusion
- Bile Duct Cancer (Cholangiocarcinoma) Analyst Views
- Bile Duct Cancer (Cholangiocarcinoma) Key Companies
- Appendix
About Us
DelveInsight is a leading healthcare-focused market research and consulting firm that provides clients with high-quality market intelligence and analysis to support informed business decisions. With a team of experienced industry experts and a deep understanding of the life sciences and healthcare sectors, we offer customized research solutions and insights to clients across the globe. Connect with us to get high-quality, accurate, and real-time intelligence to stay ahead of the growth curve.
Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Yash Bhardwaj
Email:Send Email
Phone: 09650213330
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States
Website: https://www.delveinsight.com/report-store/functional-dyspepsia-pipeline-insight
